^
    4years
    [VIRTUAL] A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). (ASCO 2020)
    This phase 2 study was initially designed as a randomized, two arm, open label study of gemcitabine and nab-paclitaxel with or without siG12D-LODER for patients with locally advanced pancreas cancer with planned 40 patients in each arm and primary endpoint of progression-free survival. Trial accrual is anticipated to be completed by December 2020. Research Funding: Silenseed
    Clinical • P2 data • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
    |
    gemcitabine • albumin-bound paclitaxel • Undisclosed KRAS-loder